Navigation Links
Widening Application Range to Boost MRI Markets in Eastern Europe, Says Frost & Sullivan
Date:10/13/2009

LONDON, Oct. 13 /PRNewswire/ -- Eastern Europe is poised to be the market to tap into in the near future for magnetic resonance imaging (MRI) manufacturers. These countries have budgets allocated to improve their healthcare systems after becoming members of the European Union (EU). Their installed base of MRI systems is not large, which directly makes this region conducive for market growth. At the same time, market prospects will receive a boost from an expanding application range.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.medicalimaging.frost.com), Western and Eastern European Markets for MRI, finds that the market earned revenues of $858.2 million in 2008 and estimates this to reach $996.3 million in 2012. The market sectors covered in this research include cardiovascular MRI, breast MRI, functional MRI, interventional MRI, contrast-enhanced MRI, spinal MRI and musculoskeletal MRI.

"Along with constant upgrades in Tesla strength, the number of applications of MRI is increasing from a research point of view," notes Frost & Sullivan Research Analyst Gideon Praveen Kumar. "Moreover, such applications are becoming commercially viable as well."

For most applications, a 1.5 Tesla system, coupled with the use of CAD, will suffice. 3-Tesla systems provide a higher resolution of images, which can prove to be important, especially for more sophisticated clinical applications. MRI scanning has also been used for ophthalmic and other sensory applications, making this a preferred route for dedicated MRI vendors.

However, reimbursement remains an industry-wide constraint for the medical imaging industry. Reimbursement for MRI scans is of considerable importance as it has one of the highest costs per procedure.

"Medical practitioners, while willing to refer more patients for MRI scans, are deterred from doing so by the low reimbursement levels which are around $500 to $800," explains Kumar. "The MRI market is particularly vulnerable to fluctuations in reimbursement levels."

Moreover, regulatory agencies worldwide prohibit individuals with implantable cardiac devices from receiving MRI scans. This further threatens market expansion.

Accordingly, cardiovascular MRI manufacturers should work towards the development of automated coil-changing systems. At the same time, they should focus on enhancing image-reconstruction techniques.

Promisingly, 3-Tesla systems are expected to grow better than projected a few years back as they do not have the inherent technical problems that they posed when first launched.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by e-mail.

Western and Eastern European Markets for MRI is part of the Medical Imaging Growth Partnership Services programme, which also includes research in the following markets: Eastern European Ultrasound Market, European Medical Imaging Equipment Market for Cardiology Applications and Eastern European Medical Imaging Modalities. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Western and Eastern European Markets for MRI

M3C6

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: +49 (0) 69 7703343
    E: katja.feick@frost.com
    http://www.frost.com

SOURCE Frost & Sullivan


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
2. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
3. Indevus Announces Submission of New Drug Application
4. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
7. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
8. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
11. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  Pennsylvania Physician General Dr. Rachel ... Programs Gary Tennis released safe prescribing ... benzodiazepines, developed with the help of a task ... are frequently prescribed for anxiety or insomnia," said ... opioid pain medications, benzodiazepines pose a significant risk ...
(Date:12/8/2016)... DANVILLE, Pa. , Dec. 8, 2016  A ... physicians reports that the use of opioid therapy to ... actually increase the likelihood of more harmful consequences, including ... Davis , M.D., and Zankhana Mehta , M.D., ... current research on chronic opioid therapy. The study was ...
(Date:12/8/2016)... CAMBRIDGE, Mass. , Dec. 8, 2016 /PRNewswire/ ... that it has obtained proof-of-mechanism for neflamapimod (previously ... recently completed Phase 2a clinical trials that demonstrated ... from Study 302 (12-week treatment) and Study 303 ... the Clinical Trials in Alzheimer,s Disease (CTAD) scientific ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):